Abstract
In the last few years three new oral anticoagulants-Dabigatran, Rivaroxaban and Apixaban and two new antiplatelet agents Prasugrel and Ticagrelor have been approved for use. Dabigatran, Rivaroxaban and Apixaban have been approved for the prevention of stroke and systemic embolism in non valvular Atrial Fibrillation in the United States. Rivaroxaban is also approved for the prevention and treatment of venous thromboembolism, including pulmonary embolism. These drugs have been shown to be non-inferior to Warfarin. These drugs do not need monitoring and have lesser drug interactions compared to Warfarin. The newer antiplatelet agents Prasugrel and Ticagrelor are more potent than Clopidogrel and are more effective in patients with CYP2 C19 enzyme deficiency. Both of these drugs are approved in acute coronary syndrome and Prasugrel is approved only in acute coronary syndrome with percutaneous coronary intervention.
Keywords: Apixaban, cardiovascular diseases, Dabigatran, newer antiplatelet agents, newer oral anticoagulants, Prasugrel, Rivaroxaban, thromboembolism, Ticagrelor.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases
Volume: 11 Issue: 3
Author(s): Sucheta Gosavi and Debabrata Mukherjee
Affiliation:
Keywords: Apixaban, cardiovascular diseases, Dabigatran, newer antiplatelet agents, newer oral anticoagulants, Prasugrel, Rivaroxaban, thromboembolism, Ticagrelor.
Abstract: In the last few years three new oral anticoagulants-Dabigatran, Rivaroxaban and Apixaban and two new antiplatelet agents Prasugrel and Ticagrelor have been approved for use. Dabigatran, Rivaroxaban and Apixaban have been approved for the prevention of stroke and systemic embolism in non valvular Atrial Fibrillation in the United States. Rivaroxaban is also approved for the prevention and treatment of venous thromboembolism, including pulmonary embolism. These drugs have been shown to be non-inferior to Warfarin. These drugs do not need monitoring and have lesser drug interactions compared to Warfarin. The newer antiplatelet agents Prasugrel and Ticagrelor are more potent than Clopidogrel and are more effective in patients with CYP2 C19 enzyme deficiency. Both of these drugs are approved in acute coronary syndrome and Prasugrel is approved only in acute coronary syndrome with percutaneous coronary intervention.
Export Options
About this article
Cite this article as:
Gosavi Sucheta and Mukherjee Debabrata, Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/18715257113119990084
DOI https://dx.doi.org/10.2174/18715257113119990084 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Current Drug Targets Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery C1 Inhibitor Administration Reduces Local Inflammation and Capillary Leakage, Without Affecting Long-term Wound Healing Parameters, in a Pig Burn Wound Model
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Insulin Therapy for Diabetes Epidemic: A Patent Review
Current Drug Delivery Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
Current Pharmaceutical Biotechnology Analgesia in PACU: Nonsteroidal Anti-Inflammatory Drugs
Current Drug Targets Recombinant Proteins and Peptides as Diagnostic and Therapeutic Reagents for Arthropod Allergies
Protein & Peptide Letters Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Editorial [Hot Topic: An Update on the Diagnosis of Allergic and Non-Allergic Drug Hypersensitivity (Executive Editors: M.T. Ventura and A. Romano) ]
Current Pharmaceutical Design Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Current Pharmaceutical Design Prevention of Bacterial Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry